Solara Active Pharma Sciences Ltd

Solara Active Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Solara Active Pharma Sciences Ltd

₹ 476 3.70%
02 Apr - close price
solara.co.in BSE: 541540 NSE: SOLARA
About

Solara Active Pharma Sciences Ltd is engaged in business of manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of APIs.[1]

It was formed through demerger of API business from Strides Shasun Ltd (currently named as Stride Pharma Sciences). Subsequently, it also acquired the human API business from Sequent Scientific Ltd during the same time, making it a pure play API company.[2]

Key Points

Product Offerings
The company is a pure-play API manufacturer, offering a range of high-value commercial APIs and contract manufacturing services across 73+ countries. Its portfolio includes 60+ commercial APIs across key therapeutic segments, including anthelmintic, anti-malaria, anti-infective, etc. The top 10 molecules contribute to 84% of its total revenues. [1] [2] [3]

Website BSE NSE
  • Market Cap ₹ 1,722 Cr.
  • Current Price ₹ 476
  • High / Low ₹ 734 / 422
  • Stock P/E
  • Book Value ₹ 347
  • Dividend Yield 0.00 %
  • ROCE 6.01 %
  • ROE 0.05 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -0.58% over past five years.
  • Company has a low return on equity of -11.5% over last 3 years.
  • Promoters have pledged 26.0% of their holding.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
395 381 352 425 212 299 363 347 300 273 319 314 349
350 332 333 388 374 290 322 286 243 228 262 279 312
Operating Profit 45 49 19 38 -162 10 42 61 58 45 57 35 37
OPM % 11% 13% 5% 9% -76% 3% 12% 18% 19% 17% 18% 11% 11%
7 5 2 -4 -62 -120 1 0 1 6 1 0 -7
Interest 24 22 25 24 25 31 31 28 27 29 24 21 22
Depreciation 28 26 26 26 26 25 25 25 25 24 24 24 26
Profit before tax 1 5 -29 -17 -275 -167 -13 8 8 -2 11 -10 -17
Tax % 22% 25% -35% 0% 0% 53% 0% 0% 0% 0% 0% 0% 0%
0 4 -19 -17 -275 -255 -13 8 8 -2 11 -10 -17
EPS in Rs 0.09 0.79 -4.07 -3.58 -57.36 -53.20 -3.74 2.22 2.24 -0.58 2.91 -2.79 -4.82
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
521 1,387 1,322 1,617 1,268 1,444 1,289 1,284 1,255
464 1,174 1,062 1,231 1,188 1,309 1,384 1,077 1,080
Operating Profit 57 213 260 386 81 134 -95 206 174
OPM % 11% 15% 20% 24% 6% 9% -7% 16% 14%
2 12 27 29 16 22 -185 8 1
Interest 25 82 78 84 75 90 105 115 96
Depreciation 34 83 94 109 112 111 103 99 98
Profit before tax 0 60 115 222 -91 -45 -488 1 -19
Tax % -70% 1% 0% 0% -36% -50% 16% 0%
0 59 115 221 -58 -22 -567 1 -19
EPS in Rs 17.30 32.01 46.22 -12.11 -4.62 -118.21 0.15 -5.28
Dividend Payout % 0% 22% 5% 11% 0% -49% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: -1%
3 Years: 0%
TTM: -4%
Compounded Profit Growth
10 Years: %
5 Years: -66%
3 Years: 26%
TTM: 94%
Stock Price CAGR
10 Years: %
5 Years: -17%
3 Years: 15%
1 Year: -7%
Return on Equity
10 Years: %
5 Years: -4%
3 Years: -11%
Last Year: 0%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 25 26 27 36 36 36 36 40 44
Reserves 739 930 1,059 1,553 1,489 1,464 898 1,054 1,210
633 538 722 621 1,037 1,013 1,012 796 646
425 466 346 404 383 386 406 342 393
Total Liabilities 1,821 1,960 2,153 2,614 2,945 2,899 2,351 2,232 2,293
1,086 1,218 1,397 1,382 1,356 1,364 1,268 1,193 1,232
CWIP 71 40 40 88 239 238 256 280 230
Investments 1 0 0 0 0 2 2 2 2
663 701 716 1,144 1,350 1,295 825 757 829
Total Assets 1,821 1,960 2,153 2,614 2,945 2,899 2,351 2,232 2,293

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
49 166 242 155 -242 156 109 213
-85 -113 -359 -106 -243 -81 -4 -37
68 -23 97 92 334 -113 -106 -180
Net Cash Flow 31 30 -20 142 -151 -38 -0 -4
Free Cash Flow 14 108 -25 -16 -451 46 69 173
CFO/OP 92% 85% 103% 49% -277% 106% -113% 104%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 184 76 63 109 141 136 99 93
Inventory Days 252 111 170 149 321 258 163 185
Days Payable 420 127 132 156 154 142 142 145
Cash Conversion Cycle 16 60 101 102 308 252 120 133
Working Capital Days -124 -22 -32 16 37 20 -128 -62
ROCE % 10% 12% 15% -0% 2% -9% 6%

Insights

In beta
Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Total Workforce (Employees & Workers)
Number

Log in to view insights

Please log in to see hidden values.

Login
Total Reactor Capacity
KL
Commercialized APIs
Number
Global DMF Filings
Number
Capacity Utilization
%
Ibuprofen Revenue Contribution
%

Shareholding Pattern

Numbers in percentages

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
40.98% 39.31% 37.19% 30.49% 30.49% 37.27% 37.27% 37.23% 37.94% 42.01% 42.01% 42.00%
19.30% 18.71% 17.86% 16.62% 15.80% 14.00% 14.25% 14.67% 14.63% 14.25% 13.58% 11.98%
2.75% 1.75% 1.79% 1.75% 2.97% 2.83% 3.37% 3.19% 2.61% 2.62% 2.69% 3.64%
36.95% 40.22% 43.16% 51.14% 50.73% 45.89% 45.11% 44.92% 44.82% 41.10% 41.71% 42.37%
No. of Shareholders 76,32575,41774,47372,91873,91277,17071,88283,14875,79174,33472,47971,890

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue

Credit ratings

Concalls